Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter/Angiotech CoSeal

This article was originally published in The Gray Sheet

Executive Summary

Surgical sealant and Adhibit surgical anti-adhesive product will be marketed by Baxter under a worldwide (excluding Japan) strategic alliance announced Feb. 25. Angiotech expects an upfront fee of $8 mil., further payments of up to $14.7 mil., and a percentage of sales "in the low double digits." The Canadian firm completed its roughly $42 mil. acquisition of product developer Cohesion Technologies in February (1"The Gray Sheet" Feb. 24, 2003, In Brief)...

You may also be interested in...



Angiotech/Baxter

Manufacturing rights for Angiotech's CoSeal surgical sealant and Adhibit surgical anti-adhesive products are granted to Baxter under an April 21 agreement. The pact expands on the firms' Feb. 25 alliance giving Baxter exclusive worldwide distribution rights, except for Japan (1"The Gray Sheet" March 3, 2003, In Brief)...

Angiotech CoSeal

U.S. clinical trials for drug-coated version of the polymer vascular surgical sealant are scheduled to begin in 2004, the company says. Angiotech Pharmaceuticals' acquisition of CoSeal developer Cohesion Technologies was completed Feb. 3 (1"The Gray Sheet" Oct. 7, 2002, p. 29). A "premixed" version of the device recently received PMA supplement approval, allowing the sealant to be loaded with an Angiotech pharmaceutical to prevent surgical adhesions. Current CoSeal improvements include easier preparation, a life span increase from 45 minutes to two hours and the ability to be stored at room temperature...

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

UsernamePublicRestriction

Register

MT017954

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel